In addition, we have shown that pathological 4R tau in MAPT intron mutation cases can be distinguishable from that in CBD and PSP cases by the analysis of the C-terminal fragments and the trypsin-resistant tau. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.